Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.

E Gabriela ChioreanKatherine A GuthriePhilip A PhilipElizabeth M SwisherFlorencia JalikisMichael J Pishvaian Jordan D BerlinMarcus S NoelJennifer M SugaIgnacio Garrido-LagunaDana Backlund CardinMarc R RadkeMai DuongShay BellaseaAndrew M Lowy Howard S Hochster

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Veliparib plus mFOLFIRI did not improve survival for metastatic pancreatic cancer. FOLFIRI should be further studied in pancreatic cancers with HR-DDR defects.

Keyphrases

phase ii study
metastatic colorectal cancer
open label
squamous cell carcinoma
placebo controlled
small cell lung cancer
wild type
locally advanced
double blind
phase iii
dna damage
phase ii
clinical trial
dna repair
randomized controlled trial
rectal cancer